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ess: m.naughton@alfreSummary Study Objectives: To compare the effect of noninvasive mechanical
ventilation (NIV) in severely acidotic with mildly acidotic patients with acute
hypercapnic chronic obstructive lung disease (COPD).
Design: Comparison of NIV in consecutively enrolled patients with acute
hypercapnic COPD with mild (pH 7.25–7.35) or severe (pHo7.25) acidosis on time
to normalise pH and improve PaCO2, duration of NIV treatment, length of stay in
hospital and survival.
Results (meadian (IQR)): Twenty-nine patients had 36 episodes of acute
hypercapnic respiratory failure: Seventeen with pHo7.25 and 19 with pH
7.25–7.34. Compared with the mildly acidotic group, the severely acidotic group
took a similar length of time for pH to normalise and PaCO2 improve (12 (6–34) vs 12
(4–28) h, respectively, P ¼ 0:42), with similar duration of NIV treatment (60 (35–96)
vs 68 (36–48) h, respectively, P ¼ 0:25) and hospital length of stay (8 (7–18) vs 9
(5–17) days, respectively, P ¼ 0:61). Overall survival was 89%, with 95% in the mild
and 82% in the severely acidotic groups.
Conclusions: Noninvasive ventilation is effective in the treatment of patients with
severe acidosis due to acute hypercapnic COPD.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Noninvasive mechanical ventilation (NIV) has been
shown to be an effective adjunct to standard
medical treatment (controlled oxygen, bronchodi-
lators, corticosteroids and antibiotics) in the
treatment of acute hypercapnic respiratory failureed.
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tive pulmonary disease (COPD).
Previous studies have shown NIV treatment to
reduce length of hospital stay1–7 and the need for
mechanical ventilation via endotracheal intubation
(MV-ETI)1–7 plus improve arterial blood gases at 1 h
faster than with standard medical treatment
alone.1–7 In reducing the need for MV-ETI, the risks
associated with this intervention (e.g. barotrauma
or ventilator-associated pneumonia) are also sig-
nificantly reduced.
Previous studies have suggested that the initial
pH upon presentation is important in determining
outcome from NIV. A large multicentre European
analysis of 1033 patients with acute hypercapnic
COPD requiring NIV suggested that if the initial pH
was o7.25, there was a significantly higher odds
ratio (OR 1.97, 95% CI 1.23–3.15) of failure with
NIV, with pH being the most important biochemical
variable.8 Moreover, if the pH measured 2 h later
was o7.25, the odds ratio of NIV failure was 21.02
(95% CI 10.07–43.87).8 Similarly, Moretti and
colleagues found that following the pre-admission
activity level, the initial pH was the strongest
physiological predictor of NIV success in a group of
137 patients with acute hypercapnic COPD.9 Squa-
drone et al.10 reported a high failure rate (63%)
with the use of NIV in a severely acidotic
(pHo7.25) group of 64 COPD patients managed in
their intensive care unit (ICU). In many studies a
pHo7.20 is regarded as an indication for ETI.11
The largest randomised controlled study examin-
ing the effects of NIV delivered in UK general
district hospital medical wards on ARF in COPD
exacerbations4 found that the subgroup of patients
with a pHo7.30 tended to have a worse outcome
when treated with NIV than less acidotic patients.
However, this study was not specifically powered
for this subgroup analysis. As a result of such data
recently published guidelines for the use of NIV
usually include pH thresholds of 7.25, below which
NIV may not be as effective and safe.12–15
The location of NIV delivery within a hospital
varies between countries16 and is influenced by
local factors including nurse (or respiratory thera-
pist) to patient ratio, monitoring facilities and
adequacy of staff training. There are variations in
the guidelines published by learned bodies includ-
ing the degree of respiratory acidosis at which NIV
can be instituted on the ward12–14 and the severity
of acidosis at which ETI should be considered.13–15
Thus, patients with severe ARF are common and
frequently present physicians with dilemmas as to
how best to manage them both in terms of the type
of respiratory support offered and the best location
for this support. Given that NIV use has becomemore widespread with increasing clinician experi-
ence over the past decade and that guidelines are
based upon data usually collected 5–10 years
earlier, we therefore sought to examine our recent
experience of the use of NIV in a dedicated nonICU
respiratory ward for patients with acute hypercap-
nic exacerbations of COPD and varying degrees of
respiratory acidosis.Methods
Consecutive patients with COPD admitted during
the 12 months of 2004 to the Alfred Hospital
Emergency Department who were treated with
standard medical treatment and had required NIV
were studied. The Alfred Hospital is a 300 bed
university-based teaching hospital and tertiary
referral centre. The study was approved by the
Alfred Hospital Ethics Committee (number 175/05)
and all patients provided informed consent.
The NIV service has been active for over 10 years
and is run by two specialist physicians with support
from one respiratory nurse specialist and one
pulmonary fellow and liaison with emergency and
intensive care wards. All patients receive NIV on
the respiratory ward staffed by nurses who receive
six monthly NIV updates and provide a nurse:
patient ratio of 1:4. Portable monitoring is avail-
able in the respiratory ward with continuous
oximetry with heart rate and regular arterial blood
gas sampling but no invasive monitoring. Close links
are maintained with a geographically separate ICU
(1:1 nurse:patient ratio) by means of an ICU liaison
team who are readily accessible. All hypercapnic
COPD patients admitted to our hospital are
referred to our service.
Patients were regarded as having COPD based
upon clinical history, radiological and lung function
and were included if they were dyspneic, hyper-
capnic (PaCO2445mmHg), acidotic (pH o7.35)
and breathing spontaneously on presentation in
the emergency department. Patients were ex-
cluded if they had cardiac instability or pulmonary
oedema, pneumothorax, impaired conscious state
(Glasgow Coma Scaleo8), inability to protect their
airway or a history of asthma as indicated by
significant reversibility to b2 agonists (improvement
in FEV1 by415% and 200ml from baseline) on prior
testing. Anthropometric data on height, weight and
derived body mass index (BMI) and long-term
oxygen therapy (LTOT) prior to admission were
recorded.
The duration of admission and need for ETI were
recorded. The initial blood gases on referral to our
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tings, time (in hours) to pH47.35 and duration of
NIV use were noted. Severity of illness was assessed
using the Simplified Acute Physiology Score II (SAPS
II),17 a severity score mainly based on physiological
parameters. Higher scores are associated with
higher probability of ICU mortality. Arterial blood
gases and respiratory rates were recorded at
initiation and after 1 h of NIV with repeat blood
gases performed 1–4 hourly until clinical stability
and improved blood gases (pH 47.35 and PaCO2
reduced) were achieved. Failure of NIV was defined
as a worsening of pH or increased PaCO2 despite
correct NIV administration, the need to protect the
airway, hemodynamic instability or agitation, in-
ability to tolerate the mask, unexpected death or if
MV-ETI was considered appropriate by the treating
team.
NIV was delivered via Vision, Synchrony or BiPAP-
ST (Respironics, Murrysville, USA) device. The
Vision was commenced in ED and then patients
were transferred to the Synchrony or BiPAP-ST for
ward use. A back-up rate of 12 breath per minute
was routinely set on the latter machines. Inspira-
tory pressure (IPAP) of 10 cmH2O and expiratory
positive airway pressure (EPAP) of 5 cm H2O were
initially set and pressures adjusted depending on
comfort, arterial blood gases and clinical response
with oxygen added to maintain SpO2 88–92%, as per
our institution’s guidelines which are based upon
published recommendations.12–15 The mask used
was usually a full face mask (Resmed, New South
Wales, Australia) initially and later changed to
nasal mask (Resmed Ultra Mirage Nasal, New South
Wales, Australia) once clinical stability and/or
improvement was achieved. Special care was taken
to ensure comfortable mask fit and adequate seal.
Standard clinical observations (respiratory and
heart rate, SpO2, blood pressure) were recorded.38 chronic NIV
68 – other diagnoses
47 acute hy
11 exclusions:-
8 not acidotic,
2 intubated in ED,
1 refused NIV 36 acu
17 pH < 7.25 - s
Figure 1 Flow diagram of pPatients were initially managed in emergency
department (ED) for 4 h and later in the respira-
tory ward. Usual treatment with antibiotics (if
clinically appropriate), steroids, bronchodilators
and oxygen plus nursing and allied healthcare
(e.g. physiotherapy) and was provided equally to
both groups.
Statistical analysis
All statistical analysis was performed using SPSS
version 11.0 (Statistical Package for Social
Sciences, Chicago, USA). All data were tested for
normality of distribution using Shapiro–Wilk W-
tests. Parametric data is expressed as mean7SD
and nonparametric data as median (IQR) unless
otherwise stated. Parametric data measured on one
occasion was compared using the unpaired Stu-
dent’s t-test and for nonparametric data compar-
isons were made for unpaired samples using the
Mann–Whitney U-test. Correlations were per-
formed using Spearman’s rank correlation test.
Chi squared was used to compare nominal data. P
valueso0.05 were accepted as statistically signifi-
cant.Results
Within the 12 month data collection period, there
were 153 patient admissions to the NIV service.
Thirty six admissions fulfilled the entry criteria of
the current study (Fig. 1). The 36 patient admis-
sions involved 29 patients, 5 patients having two
separate admissions and 1 patient having three
admissions. There were no admissions to ICU with
acute hypercapnic COPD requiring NIV during this
period.153 referrals
115 acute referrals
percapnic exacerbation COPD
te hypercapnic COPD
evere 19 pH > 7.25 - mild
atient inclusion in study.
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Table 1 Subject demographics.
Severe acidemia Mild acidemia
Number of episodes 17 19
Number on LTOT 5 6
Age (yrs) mean (SD) 67.8 (9.0) 69.6 (10.2)
BMI (kg/m2) (mean (SD)) 21.3 (4.1) 25.7 (10.3)
FEV1% predicted (mean (SD)) 28.9 (16.3) 31.3 (12.3)
FVC % predicted (mean (SD)) 61.8 (19.3) 61.7 (14.4)
SAPS II score (mean (SD)) 39.5 (12.1) 33.6 (7.9)
Number of patients with radiological evidence of pneumonia 4 3
*P&It;0.01.
Table 2 Blood gas values on admission and oxygen delivery at admission and during NIV administration (results
shown as median (IQR) unless otherwise stated).
Severe acidemia Mild acidemia
pH 7.19 (7.09–7.22) 7.30 (7.26–7.32)
PaCO2 (mmHg) 108 (90–138)
 68 (58–79)
PaO2 (mmHg) 108 (61–155) 76 (51–90)
FiO2 on admission (%) mean (SD) 0.44 (00.15) 0.32 (0.06)

PO2/FiO2 ratio on admission Mean (SD) 260 (145.9) 237 (78.7)
FiO2 on NIV (%) mean (SD) 0.35 (0.14) 0.26 (0.11)

Po0.01.
P ¼ 0:04.
F. Crummy et al.56Of the 36 patient admissions with acute hyper-
capnic COPD, there were 17 episodes with severe
acidosis and 19 episodes of mild acidosis and their
demographic data and SAPS II scores are shown in
Table 1. The two groups were similar in terms of
age, sex, BMI, spirometric values (FEV1 and FVC)
and the number in each group who had been
prescribed LTOT. There was a tendency for patients
with a severe acidosis to have higher SAPS II score
although this did not reach statistical significance
ðP ¼ 0:08Þ.
Initial blood gas values on admission, initial FiO2
and during NIV are shown in Table 2, and as
expected the pH was significantly lower and PaCO2
was significantly higher in the severe group
(Po0.01, Po0.01, respectively). While there was
no statistical difference in PaO2 between the
groups, it did tend to be higher in the more severe
group ðP ¼ 0:15Þ and a negative correlation be-
tween the pH and initial FiO2 was noted (r ¼ 0:66,
Po0.01). There was no difference between the
initial mean (SD) HCO3
 values between the severe
acidotic and mild acidotic groups (38.0 (8.4) vs 33.5
(7.1)mmol/l, P ¼ 0:08).
The changes at 1 h in respiratory rate and pH
after initiation of NIV are shown in Figs. 2 and 3,
respectively. There was a significant improvementin respiratory rate after 1 h of NIV in both the
severe acidotic (28.676.3 to 24.374.9 breaths/
min, Po0.01) and mild acidotic groups (28.577.9
to 22.576.9 breaths/min, Po0.01). There were
similarly significant improvements in pH (7.1570.1
to 7.2770.1, Po0.01) and PaCO2 (113.9743.9 to
83.9730.1mmHg, Po0.01) after 1 h of NIV in those
with severe acidosis and in those with mild acidosis
(7.2970.03 to 7.3270.04, P ¼ 0:01 and 70.7715.3
to 63.8712.1mmHg, P ¼ 0:01). There were no
significant differences between the two groups in
change in respiratory rate, pH or PaCO2 over 1 h. No
serious side-effects attributable to the use of NIV
were noted.
The median (IQR) NIV settings used were similar
in both severe and mild acidotic groups (IPAP 12
(11–13) and EPAP 6 (5–6) cmH2O). The time to
normalise pH, duration of NIV use and hospital stay
for the two groups are shown in Table 3. There were
no significant differences between the groups in
any of these indices. To investigate the possible
impact of hyperoxia on the results, admissions were
analysed in terms of patients who were relatively
hyperoxic on admission (defined arbitrarily as
PaO2470mmHg) and those who were relatively
hypoxic (PaO2o70mmHg). There were no differ-
ences between the normoxic and hyperoxic groups
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Figure 2 The change in respiratory rate at initiation and after 1 h of NIV in hypercapnic COPD patients with (a) severe
and (b) mild acidosis.
NIV in COPD with severe hypercapnic acidosis 57in terms of the pH on admission or initial PaCO2
values, the time to normalise pH, duration of NIV
use and hospital stay (Table 4).
Four patients died during the admission, three in
the severe acidotic group (initial pH values of 7.00,
7.15 and 7.19) and one in mild acidotic (initial pH
value of 7.30) group. Each of these patients had
severe end-stage COPD. Each had improved with
NIV without the need for MV-ETI (i.e. each had
normalised their pH and PaCO2 fallen), however
they were difficult to wean from NIV, volunteered
their desire for palliation and expressed a wish not
to undergo intubation. They were palliated and
subsequently died. Although the death rates were
18 and 5% in the severe and mild acidotic groups,
respectively (11% overall), all were ‘‘expected’’
and accordingly the NIV failure rate was zero. All
patients who survived the exacerbation were still
alive at 28 days.Discussion
To the best of our knowledge, this is the first study
to compare the effectiveness of NIV in patients
with severe and mild acidosis secondary to acute
hypercapnic COPD. The major finding was that the
time to normalise pH and improve PaCO2, the
duration of NIV use, length of stay in hospital and
failure rates with NIV were similar in hypercapnic
COPD groups with severe (pHo7.25) and mild (pH
7.25–7.35) acidosis. The mortality rate was 11%
overall with 5% in the mild and 18% in the severe
acidotic groups which compares favourably with
published figures of 7–62%.4,10 All such deaths were
not unexpected and included palliative care man-
agement. Importantly, this study was conducted in
a nonICU dedicated respiratory ward.
The two groups of acute hypercapnic COPD
patients were divided upon an arbitrary pH value
ARTICLE IN PRESS
Figure 3 The change in pH at initiation and after 1 h of NIV in hypercapnic COPD patients with (a) severe and (b) mild
acidosis.
Table 3 Time to normalise pH, duration of NIV
use and hospital stay (results shown as median
(IQR)).
Severe
acidemia
Mild
acidemia
Time to normalise
pH (h)
12 (4–28) 12 (6–34)
NIV duration (h) 48 (36–68) 60 (35–96)
Length of stay
(days)
9 (5–17) 8 (7–18)
F. Crummy et al.58of 7.25. This value was derived from both published
guidelines14 and from a previous study suggesting
that patients with acute COPD and a pHo7.25 have
a significantly greater mortality compared withpatients with pH47.25.18 However, in the latter
study the more acidotic patients were also noted to
be more hypotensive and uraemic suggesting that
they may have been more systemically unwell.
None of the patients included in our study were
hypotensive or had significant renal impairment.
We observed no difference between the two groups
in terms of lung function, BMI, age and frequency of
prior use of LTOT. However, the severe acidotic
group had a tendency to have a higher SAPS II score
than the mild acidotic group indicating a more
severe acute presentation.
It is known that initial low pH is an indicator of
NIV failure8,9 and that in many studies a low pH
(o7.25) would signal the need for MV-ETI.11 Other
studies suggest that the change in pH is predictive
of success.19 All patients with severe acidosis in our
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Table 4 The effects of initial oxygenation on time to normalise pH, duration of NIV use and length of hospital
stay (results shown as median (IQR)).
PaO2o70mmHg PaO2470mmHg
ðn ¼ 14Þ ðn ¼ 22Þ
PH 7.26 (7.19–7.32) 7.25 (7.18–7.28)
PO2 (mmHg) 50 (46–60)
 96 (82–134)
PCO2 (mmHg) 88 (64–112) 80 (61–109)
Time to normalise pH (h) 12 (5–34) 13.5 (6–33)
NIV duration (h) 55 (45–110) 47 (32–73)
Length of stay (days) 10 (7–17) 9 (6–18)
Po0.01.
NIV in COPD with severe hypercapnic acidosis 59study had a good initial response to NIV as shown by
the improvements in pH after 1 h of NIV and
therefore were more likely to succeed with this
modality. It must also be acknowledged that some
patients had multiple admissions and thus there may
have been a learning effect in that these patients
were perhaps more likely to succeed with NIV.
Although the two groups had similar initial PaO2
values, we noted a significant negative correlation
between pH and FiO2 suggesting the possibility that
the degree of acidosis may be related to the initial
FiO2. This finding has been reported by other
investigators.20 Whether the hyperoxic group in
our study would have normalised their pH and
PaCO2 values with back titration of oxygen without
the need for NIV was not tested. Indeed we are not
aware of any study which has specifically addressed
the issue as to whether back-titration of oxygen
alone would satisfactorily treat acute respiratory
failure in this group of patients. In addition, the
fact that there was no difference in time to
normalise pH, duration of NIV use or length of
hospital stay between patients who were hyper-
oxic, and those who were not, would suggest that
hyperoxic patients are not different from other
patients in terms of their likelihood of NIV success.
Plant et al.20 noted that only 20% of their mildly
acidotic patients (pH 7.25–7.35) normalised their
pH without the need for NIV. Moreover, Moloney
et al.21 have reported only 13% COPD patients
with an acute hypercapnic exacerbation developed
worsening of hypercapnia with controlled oxygen
therapy. Thus, the likelihood of hyperoxia as being
the main or only contributor to NIV success in our
study is unlikely.
The long-term morbidity and mortality of those
who suffer acute respiratory failure is known to be
very high. Of those who survive an episode of ARF
requiring NIV, 80% will be admitted in the sub-
sequent year and 50% will have died in the same
period.22 Within hospital mortality for patients with
severe COPD is estimated to be 12%,20 which isnot dissimilar to the overall 11% mortality we
observed. Of note, the mortality rate was higher in
the severe acidotic group compared with the mild
acidotic group (18 vs 5%) but as stated above, all
patients who died, did so with palliative intent due
to extremely severe and disabling end-stage COPD.
In a study specifically examining the outcome of
severely acidotic patients in an ICU setting Squa-
drone et al.10 compared 64 patients with hyper-
capnic respiratory failure due to an exacerbation of
COPD (mean age 70 years, pH 7.18 and FEV1
35% predicted normal) who received NIV to a
historical matched group who had been treated
with MV-ETI. NIV failed in 40 (62.5%) patients who
went on to be intubated. Conti et al.11 undertook a
prospective randomised trial of NIV vs MV-ETI in an
ICU setting in acidemic hypercapnic COPD patients
with similar age (72 years), FEV1 (30%), PaCO2
(86mmHg) and pH (7.20) to those in our study
group. Their overall mortality was 22%, NIV failure
(requiring MV-ETI) was 52%, average length of NIV
treatment was 28 h and average ICU length of stay 7
days. In comparison, although our severe acidemic
group had similar mortality (18%), important
differences were the absence of NIV failure and
longer mean NIV use (48 h) yet similar hospital
length of stay (9 days) without the need for ICU.
Thus, important differences exist in the NIV failure
rates of Conti and in our series. The reasons for this
are not entirely clear to us. It is known that studies
performed in an ICU setting tend to have higher
rates of MV-ETI despite similar blood gas data.23
Patients who are treated promptly and efficiently
in ED and on the nonICU wards may well respond
quickly to standard medical and NIV therapy and
thus may have better outcomes than those who
remain acidotic despite multiple interventions and
are subsequently managed in the ICU. Avoiding the
noisy sleep disturbing environment of ICU may also
be advantageous24 and a formal study to compare
NIV delivery in ICU vs a respiratory ward would be
of great interest.
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allows greater use of NIV outside of an ICU setting.
Carlucci et al.25 reported the in-hospital NIV failure
to be 17% and overall mortality 8% in 248 patients
with acute hypercapnic COPD (mean pH 7.23,
PaCO2 86mmHg) over a 7 year period. Impor-
tantly, they noted that the use of NIV outside the
ICU ward was increasing in patients with a greater
severity of respiratory disease without alterations
to survival rates. The shift from ICU dominated to a
combined ICU and medical ward use of NIV was
rewarded by 16% reduction in daily healthcare
costs. The authors comment that while initial pH
may be a predictive factor in the treatment of ARF,
factors such as staff familiarity with the use of NIV
and refinements of its use over a period of time may
be more important and influence greatly the
chance of success of NIV in a particular unit. Thus,
it is possible that the results we achieved may not
be found in an institution with less experience,
regardless of the actual location of delivery.
It is important that institution of a trial of NIV
does not delay other therapies including MV-ETI if
necessary. Squadrone et al.10 showed that in
severely acidotic patients in whom NIV succeeded
there was a significant reduction in ICU mortality,
ICU stay and serious complications as compared to
those who required MV-ETI. When comparison was
made between those who failed NIV and went on to
be intubated and those who were initially intu-
bated there were no significant differences in ICU
or hospital mortality or in the numbers who
developed serious complications. This would sug-
gest that in this group of patients a trial of NIV is
worthwhile in view of the reduction in serious
complications in the patients who succeed. It also
demonstrates that a trial of NIV is not detrimental
to the outcome as compared to patients who are
intubated immediately.
In summary, this study provides strong data that
the provision of NIV is similarly effective in severe
and mild acidotic hypercapnic COPD patients.
Second, this can be achieved in a nonICU respira-
tory ward with educated staff. Whether this is
related to the experience of the unit providing care
is as yet unknown. However, given the prevalence
of patients presenting with severe respiratory
acidosis and the current controversies regarding
this group, this is an area which deserves further
study.Acknowledgements
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